• Researchers Estimate The Number of People Globally Living With Chronic Obstructive pulmonary Disease (COPD) Will Hit 600 Million By 2050.
  • There are Certain Risk Factors for Copd, Including Obesity and Having Type 2 Diabetes.
  • A New Study Has Found That People Who Have Type 2 Diabetes Who Are Treeped With Glp-1 and Sglt-2 Medications have to Lower Risk of Having Copd Symptom Flare-UpS Than Hosso Taking Taking DPP-4 Drugs.

Researchers Estimate That As of 2019, About 400 Million People Around the World Were Living With Chronic Obstructive pulmonary disease (COPD), with that snumber Experienced to hit 600 million by 2050.

WHILE ANYONE MIGHT DEVELOP COPD, there are certain RISK FACTORS THAT MAY INCREASE TO PERSON’S CHANCE OF DEVELOPING THIS CHRONIC DIRE Obesity and Type 2 Diabetes.

Past Research Shows That More than One-Third of People Who Have Copd Also Have Obesity, As This Condition May Have a Negative Impact On A Person’s Airflow and Thus increase and Obesity Hypoventilation Syndrome.

A STUDY PUBLISHED IN MAY 2023 FURTER FOUNT THAT WHO WHO HAVE TYPE 2 DIABETES HAV A 35% Higher Risk OF DEVELOPING COPD THAN SUMANON WHHO DOES NOT.

Now, a New Study Published in Jama Internal Medicine Reports that People Who has type 2 diabetes and are treated with Sodium-glucose Cotransporter-2 Inhibitors (SGLT-2is) Or glucagon-Like peptide-1 recipient agonists (LPG-1ras)-Like ozempic and wegovy-may be at a Lower risk of moderate or severe copd exacerbations, or symptom Flare-ups, compared to thhu taking Dipeptidyl peptide 4 inhibitors (DPP-4is).

COPD RISKS: WHY FOCUS ON LPG-1 AND OTHER DIABETES MEDICATIONS?

For This Study, Refracchers Analyzed Medical Data from Almost 394,000 ADULTS 40 YEARS AND OLDER WITH TYPE 2 DIABETES AND ACTICE COPD THAT WERE TAKING GLP-1, SGLT-2, OR DPP-4I MEDICATIONS.

Elisabetta Patorno, MD, DRPH, Associate Professor of Medicine at Hes ) At the Division of PharmacoEpidemiology at Brigham and Women’s In Boston Hospital, Senior Author of This Study, Told Medical News Today:

“We Explored The Link Between GLP-1, SGLT-2i Medications, and Copd Exacerbation Risk Becouse Prior Research SuggestaSSE Drugs Might have anti-inflammatory and lung-prototefe efforts. However, There Was Limited Clinical Evidence Comparing The Impact On Copd Outcomes in Patients With Type 2 Diabetes. ”

“Refers Continue Studying LP-1 Medications Beyond Diabetes and Weight Loss Best they may have Additional Health Benefits, Such As Reducting Inflammation, Improving Lung Lung Function, and Lowering The Risk of Conditions Like Copd Exacerbations,” Added Avik Ray, MS, MS, MS, MS FELLOW AT THE DIVISION OF PHARMACOEPIDEMIOLOGY AT BRIGAM AND Women’s and Harvard Medical School, First Author of this Study.

“Underestanding these Effects Can Help Patients with these conditions,” I have added.

LPG-1S, SGLT-2S LINKED TO LOWER RISK OF COPD FLARE-UPS

At the conclusion of the study, Refound that Study participants with type 2 diabetes and copd who took glp-1 or sglt-2 Medications Had a Lower Risk of Having Moderate or Severe Copd Exacerbations When Combase To participants Taking DPP-4i Drugs.

“The Finding that SGLT-2i and GLP-1ras Lower Copd Exacerbation Risk Combrad To DPP-4I Suggests these Medications Could Be Better Options for Patients With Diabetes and Copd,” Patorno Said. “This could influence treatment decisions and improvisatory health in This High-Risk Population.”

“LPG-1 Medications Might Help Lower Copd Exacerbation Risk by Reducting Systemic Inflammation, Improving Metabolic Function, and Possibly Having Direct Effects on Lung Tissue,” She continues. “Their Impact on Weight Loss and Cardiovascular Health Could Also contributes to Better Overall Respiratory outcomes.”

“BeSe Findings May finding doctors to Prioritize Sglt-2i Or LPG-1ras Over DPP-4i for Patients with Type 2 Diabetes and Copd,” Ray Said. “By Consido the Added Respiratory Benefits, Physicans Can Optimize Treatment Choices for Both Diabetes and Lung Health.”

“The Next Steps (for This Research) Include behavioring Further Research to ConfirmSe Findings in OTher Real-World DataSets, Exploreing The Biological Mechanisms Behind Tosese Benefits, and Assessing the Long-Term Impact of First Medications on Copd Progress,” I have add. ”

Long-Term Safety Data Needed

MNT Had the Opportunity To Speak with Fady Youssef, MD, A Board-Certified Pulmonologist, Interist and Critical Care Specialist at Memorialcare Long Beach Medical Center in Long Beach, CA, About This Study.

Youssef Commented that it is Known That Obesity Affects Lung Function and Does Make Obstructive Lung Disease Such As Copd and Asthma Much More Difficult To Control, and So It is not yet Clear if the Effect of the Drug Had To do with the weight loss and its Effect on Copd, or it had different mechanism of action.

“There’s a Lot of Hype and Excitement Around GLP-1 and Like Medications,” Youssef. “And The Thing I want to see is long-term Safety Data. Whenever We Give Medication to a Large Portion of the Population Without Long-Term Safety, One is Concerned About What Those Long-Term Safety Signals are Going To Be. ”

“Copd exacerbations carry significant morbidity and significant cost of the Healthcare System, and so i was like to see data to prevent, to figure out We we can minimize the incident of copd as a new patient developing copd,” I have add. “And if we can” Prevent it from Happening, Figuring Out Control and Minimizing Exacerbations. ”